A review of pharmacological interactions between HIV or hepatitis C virus medications and opioid agonist therapy: Implications and management for clinical practice

Expert Review of Clinical Pharmacology

Volumn 6, Issue 3, 2013, Pages 249-269

  Bruce, R Douglas ^a,b   Moody, David E ^c   Altice, Frederick L ^a,b   Gourevitch, Marc N ^d   Friedland, Gerald H ^a,b  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b YALE UNIVERSITY   (United States)

^c UNIVERSITY OF UTAH   (United States)

^d NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

antiretroviral therapy; buprenorphine; drug interactions; drug metabolism; hepatitis C; HIV AIDS; methadone; pharmacodynamics; pharmacokinetic

Indexed keywords

2 ETHYL 5 METHYL 3,3 DIPHENYLPYRROLINE; 2 ETHYLIDINE 1,5 DIMETHYL 3,3 DIPHENYLPYRROLIDINE; ABACAVIR; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTIVIRUS AGENT; ATAZANAVIR; BUPRENORPHINE; CYTOCHROME P450; DELAVIRDINE; DIDANOSINE; DRUG METABOLITE; EFAVIRENZ; ETRAVIRINE; LAMIVUDINE; LERSIVIRINE; METHADONE; MULTIDRUG RESISTANCE PROTEIN; NEVIRAPINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; NORBUPRENORPHINE; OPIATE AGONIST; PROTEINASE INHIBITOR; RILPIVIRINE; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TENOFOVIR; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZALCITABINE; ZIDOVUDINE;

ANEMIA; AREA UNDER THE CURVE; CLINICAL PRACTICE; DRUG BLOOD LEVEL; DRUG CONJUGATION; DRUG DISPOSITION; DRUG EFFICACY; DRUG EXCRETION; DRUG GLUCURONIDATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG OXIDATION; HEADACHE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER METABOLISM; NONHUMAN; REVIEW; WITHDRAWAL SYNDROME;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ANALGESICS, OPIOID; ANTI-RETROVIRAL AGENTS; BUPRENORPHINE; DRUG INTERACTIONS; HEPATITIS C; HIV INFECTIONS; HUMANS; METHADONE; OPIATE SUBSTITUTION TREATMENT; RECEPTORS, OPIOID;

EID: 84877597257     PISSN: 17512433     EISSN: 17512441     Source Type: Journal    
DOI: 10.1586/ecp.13.18     Document Type: Review

References (200)

1. Abdala N, Carney JM, Durante AJ et al. Estimating the prevalence of syringe-borne and sexually transmitted diseases among injection drug users in St Petersburg, Russia. Int. J. STD AIDS 14(10), 697-703 (2003).
2. Kelly JA, Amirkhanian YA. The newest epidemic: a review of HIV/AIDS in Central and Eastern Europe. Int. J. STD AIDS 14(6), 361-371 (2003).
3. Caiaffa WT, Proietti FA, Carneiro-Proietti AB et al.; Epidemiological Study of Injection Drug Users in Brazil (AjUDEBrasil Project). The dynamics of the human immunodeficiency virus epidemics in the south of Brazil: increasing role of injection drug users. Clin. Infect. Dis. 37(Suppl. 5), S376-S381 (2003).
4. Zhang C, Yang R, Xia X et al. High prevalence of HIV-1 and hepatitis C virus coinfection among injection drug users in the southeastern region of Yunnan, China. J. Acquir. Immune Defic. Syndr. 29(2), 191-196 (2002).
5. Averhoff FM, Glass N, Holtzman D. Global burden of hepatitis C: considerations for healthcare providers in the United States. Clin. Infect. Dis. 55(Suppl. 1), S10-S15 (2012).
6. Morineau G, Bollen LJ, Syafitri RI, Nurjannah N, Mustikawati DE, Magnani R. HIV prevalence and risk behaviours among injecting drug users in six Indonesian cities implications for future HIV prevention programs. Harm Reduct. J. 9(1), 37 (2012).
7. United Nations Office on Drugs and Crime. World Drug Report E.12.XI.1 United Nations Office on Drugs and Crime, Vienna, Austria (2012).
8. Nelson PK, Mathers BM, Cowie B et al. Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews. Lancet 378(9791), 571-583 (2011).
9. Hart GJ, Sonnex C, Petherick A, Johnson AM, Feinmann C, Adler MW. Risk behaviours for HIV infection among injecting drug users attending a drug dependency clinic. BMJ 298(6680), 1081-1083 (1989).
10. Dolan K, Hall W, Wodak A. Methadone maintenance reduces injecting in prison. BMJ 312(7039), 1162 (1996).
11. Donny EC, Walsh SL, Bigelow GE, Eissenberg T, Stitzer ML. High-dose methadone produces superior opioid blockade and comparable withdrawal suppression to lower doses in opioiddependent humans. Psychopharmacology (Berl.) 161(2), 202-212 (2002).
12. Fiellin DA, O'Connor PG. Clinical practice. Office-based treatment of opioid-dependent patients. N. Engl. J. Med. 347(11), 817-823 (2002).
13. Bruce RD. Methadone as HIV prevention: high volume methadone sites to decrease HIV incidence rates in resource limited settings. Int. J. Drug Policy 21(2), 122-124 (2010).
14. Altice FL, Kamarulzaman A, Soriano VV, Schechter M, Friedland GH. Treatment of medical, psychiatric, and substance-use comorbidities in people infected with HIV who use drugs. Lancet 376(9738), 367-387 (2010).
15. Friedland G, Vlahov D. Integration of buprenorphine for substance-abuse treatment by HIV care providers. J. Acquir. Immune Defic. Syndr. 56(Suppl. 1), S1-S2 (2011).
16. Bruce RD, Eiserman J, Acosta A, Gote C, Lim JK, Altice FL. Developing a modified directly observed therapy intervention for hepatitis C treatment in a methadone maintenance program: implications for program replication. Am. J. Drug Alcohol Abuse 38(3), 206-212 (2012).
17. Cohen MS, Chen YQ, McCauley M et al.; HPTN 052 Study Team. Prevention of HIV-1 infection with early antiretroviral therapy. N. Engl. J. Med. 365(6), 493-505 (2011).
18. Lee HY, Li JH, Wu LT, Wu JS, Yen CF, Tang HP. Survey of methadone-drug interactions among patients of methadone maintenance treatment program in Taiwan. Subst. Abuse Treat. Prev. Pol. 7, 11 (2012).
19. Bruce RD, Altice FL, Gourevitch MN, Friedland GH. Pharmacokinetic drug interactions between opioid agonist therapy and antiretroviral medications: implications and management for clinical practice. J. Acquir. Immune Defic. Syndr. 41(5), 563-572 (2006).
20. Gonzalez F, Coughtrie M, Tukey RH. Drug metabolism. In: Goodman & Gilman's The Pharmacological Basis of Therapeutics. Goodman LS, Brunton LL, Chabner B, Knollmann BC (Eds). McGraw-Hill, NY, USA, 2084 (2011).
21. Brown SM, Campbell SD, Crafford A, Regina KJ, Holtzman MJ, Kharasch ED. P-glycoprotein is a major determinant of norbuprenorphine brain exposure and antinociception. J. Pharmacol. Exp. Ther. 343(1), 53-61 (2012).
22. Brown SM, Holtzman M, Kim T, Kharasch ED. Buprenorphine metabolites, buprenorphine-3-glucuronide and norbuprenorphine-3-glucuronide, are biologically active. Anesthesiology 115(6), 1251-1260 (2011).
23. Tournier N, Chevillard L, Megarbane B, Pirnay S, Scherrmann JM, Declèves X. Interaction of drugs of abuse and maintenance treatments with human P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2). Int. J. Neuropsychopharmacol. 13(7), 905-915 (2010).
24. Alhaddad H, Cisternino S, Declèves X et al. Respiratory toxicity of buprenorphine results from the blockage of P-glycoproteinmediated efflux of norbuprenorphine at the blood-brain barrier in mice. Crit. Care Med. 40(12), 3215-3223 (2012).
25. Yassen A, Kan J, Olofsen E, Suidgeest E, Dahan A, Danhof M. Pharmacokinetic-pharmacodynamic modeling of the respiratory depressant effect of norbuprenorphine in rats. J. Pharmacol. Exp. Ther. 321(2), 598-607 (2007).
26. Mégarbane B, Marie N, Pirnay S et al. Buprenorphine is protective against the depressive effects of norbuprenorphine on ventilation. Toxicol. Appl. Pharmacol. 212(3), 256-267 (2006).
27. Moody DE, Fang WB, Morrison J, McCance-Katz E. Gender differences in pharmacokinetics of maintenance dosed buprenorphine. Drug Alcohol Depend. 118(2-3), 479-483 (2011).
28. Inturrisi CE, Verebely K. Disposition of methadone in man after a single oral dose. Clin. Pharmacol. Ther. 13(6), 923-930 (1972).
29. Scott CC, Robbins EB, Chen KK. Pharmacologic comparison of the optical isomers of methadon. J. Pharmacol. Exp. Ther. 93(3), 282-286 (1948).
30. Kristensen K, Christensen CB, Christrup LL. The 12 opioid receptor binding profiles of methadone stereoisomers and morphine. Life Sci. 56(2), PL45-PL50 (1995).
31. Pohland A, Boaz HE, Sullivan HR. Synthesis and identification of metabolites resulting from the biotransformation of dl-methadone in man and in the rat. J. Med. Chem. 14(3), 194-197 (1971).
32. Pert CB, Snyder SH. Opiate receptor: demonstration in nervous tissue. Science 179(4077), 1011-1014 (1973).
33. Horng JS, Smits SE, Wong DT. The binding of the optical isomers of methadone, α-methadol, β-acetylmethadol and their N-demethylated derivatives to the opiate receptors of rat brain. Res. Commun. Chem. Pathol. Pharmacol. 14(4), 621-629 (1976).
34. Lötsch J, Skarke C, Wieting J et al. Modulation of the central nervous effects of levomethadone by genetic polymorphisms potentially affecting its metabolism, distribution, and drug action. Clin. Pharmacol. Ther. 79(1), 72-89 (2006).
35. Lin C, Somberg T, Molnar J, Somberg J. The effects of chiral isolates of methadone on the cardiac potassium channel IKr. Cardiology 113(1), 59-65 (2009).
36. Eap CB, Crettol S, Rougier JS et al. Stereoselective block of hERG channel by (S)-methadone and QT interval prolongation in CYP2B6 slow metabolizers. Clin. Pharmacol. Ther. 81(5), 719-728 (2007).
37. Wang JS, DeVane CL. Involvement of CYP3A4, CYP2C8, and CYP2D6 in the metabolism of (R)-and (S)-methadone in vitro. Drug Metab. Dispos. 31(6), 742-747 (2003).
38. Moody DE, Alburges ME, Parker RJ, Collins JM, Strong JM. The involvement of cytochrome P450 3A4 in the N-demethylation of L-acetylmethadol (LAAM), norLAAM, and methadone. Drug Metab. Dispos. 25(12), 1347-1353 (1997).
39. Gerber JG, Rhodes RJ, Gal J. Stereoselective metabolism of methadone N-demethylation by cytochrome P4502B6 and 2C19. Chirality 16(1), 36-44 (2004).
40. Kharasch ED, Hoffer C, Whittington D, Sheffels P. Role of hepatic and intestinal cytochrome P450 3A and 2B6 in the metabolism, disposition, and miotic effects of methadone. Clin. Pharmacol. Ther. 76(3), 250-269 (2004).
41. Totah RA, Sheffels P, Roberts T, Whittington D, Thummel K, Kharasch ED. Role of CYP2B6 in stereoselective human methadone metabolism. Anesthesiology 108(3), 363-374 (2008).
42. Chang Y, Fang WB, Lin SN, Moody DE. Stereo-selective metabolism of methadone by human liver microsomes and cDNAexpressed cytochrome P450s: a reconciliation. Basic Clin. Pharmacol. Toxicol. 108(1), 55-62 (2011).
43. Iribarne C, Berthou F, Baird S et al. Involvement of cytochrome P450 3A4 enzyme in the N-demethylation of methadone in human liver microsomes. Chem. Res. Toxicol. 9(2), 365-373 (1996).
44. Begré S, von Bardeleben U, Ladewig D et al. Paroxetine increases steady-state concentrations of (R)-methadone in CYP2D6 extensive but not poor metabolizers. J. Clin. Psychopharmacol. 22(2), 211-215 (2002).
45. Kharasch ED, Bedynek PS, Hoffer C, Walker A, Whittington D. Lack of indinavir effects on methadone disposition despite inhibition of hepatic and intestinal cytochrome P4503A (CYP3A). Anesthesiology 116(2), 432-447 (2012).
46. Kharasch ED, Whittington D, Ensign D et al. Mechanism of efavirenz influence on methadone pharmacokinetics and pharmacodynamics. Clin. Pharmacol. Ther. 91(4), 673-684 (2012).
47. Foster DJ, Somogyi AA, Bochner F. Methadone N-demethylation in human liver microsomes: lack of stereoselectivity and involvement of CYP3A4. Br. J. Clin. Pharmacol. 47(4), 403-412 (1999).
48. Prost F, Thormann W. Capillary electrophoresis to assess drug metabolism induced in vitro using single CYP450 enzymes (Supersomes): application to the chiral metabolism of mephenytoin and methadone. Electrophoresis 24(15), 2577-2587 (2003).
49. Shinderman M, Maxwell S, Brawand-Amey M, Golay KP, Baumann P, Eap CB. Cytochrome P4503A4 metabolic activity, methadone blood concentrations, and methadone doses. Drug Alcohol Depend. 69(2), 205-211 (2003).
50. Shiran MR, Lennard MS, Iqbal MZ et al. Contribution of the activities of CYP3A, CYP2D6, CYP1A2 and other potential covariates to the disposition of methadone in patients undergoing methadone maintenance treatment. Br. J. Clin. Pharmacol. 67(1), 29-37 (2009).
51. Crettol S, Déglon JJ, Besson J et al. ABCB1 and cytochrome P450 genotypes and phenotypes: influence on methadone plasma levels and response to treatment. Clin. Pharmacol. Ther. 80(6), 668-681 (2006).
52. Wang SC, Ho IK, Tsou HH et al. CYP2B6 polymorphisms influence the plasma concentration and clearance of the methadone S-enantiomer. J. Clin. Psychopharmacol. 31(4), 463-469 (2011).
53. Crettol S, Déglon JJ, Besson J et al. Methadone enantiomer plasma levels, CYP2B6, CYP2C19, and CYP2C9 genotypes, and response to treatment. Clin. Pharmacol. Ther. 78(6), 593-604 (2005).
54. Dobrinas M, Crettol S, Oneda B et al. Contribution of CYP2B6 alleles in explaining extreme (S)-methadone plasma levels: a CYP2B6 gene resequencing study. Pharmacogenet. Genomics 23(2), 84-93 (2013).
55. Hung CC, Chiou MH, Huang BH et al. Impact of genetic polymorphisms in ABCB1, CYP2B6, OPRM1, ANKK1 and DRD2 genes on methadone therapy in Han Chinese patients. Pharmacogenomics 12(11), 1525-1533 (2011).
56. Fonseca F, De La Torre R, Diaz L et al. Contribution of cytochrome P450 and ABCB1 genetic variability on methadone pharmacokinetics, dose requirements, and response. PLoS One 6(5), e19527 (2011).
57. Levran O, Peles E, Hamon S, Randesi M, Adelson M, Kreek MJ. CYP2B6 SNPs are associated with methadone dose required for effective treatment of opioid addiction. Addict. Biol. doi:10.1111/j.1369-1600.2011.00349.x (2011) (Epub ahead of print).
58. Bunten H, Liang WJ, Pounder D, Seneviratne C, Osselton MD. CYP2B6 and OPRM1 gene variations predict methadone-related deaths. Addict. Biol. 16(1), 142-144 (2011).
59. Stringer J, Welsh C, Tommasello A. Methadone-associated Q-T interval prolongation and torsades de pointes. Am. J. Health Syst. Pharm. 66(9), 825-833 (2009).
60. Eap CB, Broly F, Mino A et al. Cytochrome P450 2D6 genotype and methadone steady-state concentrations. J. Clin. Psychopharmacol. 21(2), 229-234 (2001).
61. Kharasch ED, Walker A, Whittington D, Hoffer C, Bedynek PS. Methadone metabolism and clearance are induced by nelfinavir despite inhibition of cytochrome P4503A (CYP3A) activity. Drug Alcohol Depend. 101(3), 158-168 (2009).
62. Kharasch ED, Bedynek PS, Park S, Whittington D, Walker A, Hoffer C. Mechanism of ritonavir changes in methadone pharmacokinetics and pharmacodynamics: I. Evidence against CYP3A mediation of methadone clearance. Clin. Pharmacol. Ther. 84(4), 497-505 (2008).
63. Kirby BJ, Collier AC, Kharasch ED et al. Complex drug interactions of HIV protease inhibitors 2: in vivo induction and in vitro to in vivo correlation of induction of cytochrome P450 1A2, 2B6, and 2C9 by ritonavir or nelfinavir. Drug Metab. Dispos. 39(12), 2329-2337 (2011).
64. Verebely K, Volavka J, Mulé S, Resnick R. Methadone in man: pharmacokinetic and excretion studies in acute and chronic treatment. Clin. Pharmacol. Ther. 18(2), 180-190 (1975).
65. Gelston EA, Coller JK, Lopatko OV et al. Methadone inhibits CYP2D6 and UGT2B7/2B4 in vivo: a study using codeine in methadone-and buprenorphinemaintained subjects. Br. J. Clin. Pharmacol. 73(5), 786-794 (2012).
66. Lu WJ, Bies R, Kamden LK, Desta Z, Flockhart DA. Methadone: a substrate and mechanism-based inhibitor of CYP19 (aromatase). Drug Metab. Dispos. 38(8), 1308-1313 (2010).
67. Eap CB, Buclin T, Baumann P. Interindividual variability of the clinical pharmacokinetics of methadone: implications for the treatment of opioid dependence. Clin. Pharmacokinet. 41(14), 1153-1193 (2002).
68. Levran O, O'Hara K, Peles E et al. ABCB1 (MDR1) genetic variants are associated with methadone doses required for effective treatment of heroin dependence. Hum. Mol. Genet. 17(14), 2219-2227 (2008).
69. Cone EJ, Gorodetzky CW, Yousefnejad D, Buchwald WF, Johnson RE. The metabolism and excretion of buprenorphine in humans. Drug Metab. Dispos. 12(5), 577-581 (1984).
70. Iribarne C, Picart D, Dréano Y, Bail JP, Berthou F. Involvement of cytochrome P450 3A4 in N-dealkylation of buprenorphine in human liver microsomes. Life Sci. 60(22), 1953-1964 (1997).
71. Kobayashi K, Yamamoto T, Chiba K et al. Human buprenorphine N-dealkylation is catalyzed by cytochrome P450 3A4. Drug Metab. Dispos. 26(8), 818-821 (1998).
72. Moody DE, Slawson MH, Strain EC, Laycock JD, Spanbauer AC, Foltz RL. A liquid chromatographic-electrospray ionization-tandem mass spectrometric method for determination of buprenorphine, its metabolite, norbuprenorphine, and a coformulant, naloxone, that is suitable for in vivo and in vitro metabolism studies. Anal. Biochem. 306(1), 31-39 (2002).
73. Picard N, Cresteil T, Djebli N, Marquet P. In vitro metabolism study of buprenorphine: evidence for new metabolic pathways. Drug Metab. Dispos. 33(5), 689-695 (2005).
74. Chang Y, Moody DE, McCance-Katz EF. Novel metabolites of buprenorphine detected in human liver microsomes and human urine. Drug Metab. Dispos. 34(3), 440-448 (2006).
75. Moody DE, Chang Y, Huang W, McCance-Katz EF. The in vivo response of novel buprenorphine metabolites, M1 and M3, to antiretroviral inducers and inhibitors of buprenorphine metabolism. Basic Clin. Pharmacol. Toxicol. 105(3), 211-215 (2009).
76. Chang Y, Moody DE. Glucuronidation of buprenorphine and norbuprenorphine by human liver microsomes and UDP-glucuronosyltransferases. Drug Metab. Lett. 3(2), 101-107 (2009).
77. Rouguieg K, Picard N, Sauvage FL, Gaulier JM, Marquet P. Contribution of the different UDP-glucuronosyltransferase (UGT) isoforms to buprenorphine and norbuprenorphine metabolism and relationship with the main UGT polymorphisms in a bank of human liver microsomes. Drug Metab. Dispos. 38(1), 40-45 (2010).
78. Huang W, Moody DE, McCance-Katz EF. The in vivo glucuronidation of buprenorphine and norbuprenorphine determined by liquid chromatography- electrospray ionization-tandem mass spectrometry. Ther. Drug Monit. 28(2), 245-251 (2006).
79. Umehara K, Shimokawa Y, Miyamoto G. Inhibition of human drug metabolizing cytochrome P450 by buprenorphine. Biol. Pharm. Bull. 25(5), 682-685 (2002).
80. Zhang W, Ramamoorthy Y, Tyndale RF, Sellers EM. Interaction of buprenorphine and its metabolite norbuprenorphine with cytochromes p450 in vitro. Drug Metab. Dispos. 31(6), 768-772 (2003).
81. Ohtani M, Kotaki H, Sawada Y, Iga T. Comparative analysis of buprenorphineand norbuprenorphine-induced analgesic effects based on pharmacokinetic-pharmacodynamic modeling. J. Pharmacol. Exp. Ther. 272(2), 505-510 (1995).
82. Huang P, Kehner GB, Cowan A, Liu-Chen LY. Comparison of pharmacological activities of buprenorphine and norbuprenorphine: norbuprenorphine is a potent opioid agonist. J. Pharmacol. Exp. Ther. 297(2), 688-695 (2001).
83. Sommadossi JP. Cellular nucleoside pharmacokinetics and pharmacology: a potentially important determinant of antiretroviral efficacy. AIDS 12(Suppl. 3), S1-S8 (1998).
84. Beach JW. Chemotherapeutic agents for human immunodeficiency virus infection: mechanism of action, pharmacokinetics, metabolism, and adverse reactions. Clin. Ther. 20(1), 2-25; discussion l (1998).
85. Veal GJ, Back DJ. Metabolism of Zidovudine. Gen. Pharmacol. 26(7), 1469-1475 (1995).
86. Deeks SG, Barditch-Crovo P, Lietman PS et al. Safety, pharmacokinetics, and antiretroviral activity of intravenous 9-[2-(R)-(phosphonomethoxy)propyl] adenine, a novel anti-human immunodeficiency virus (HIV) therapy, in HIV-infected adults. Antimicrob. Agents Chemother. 42(9), 2380-2384 (1998).
87. Heald AE, Hsyu PH, Yuen GJ, Robinson P, Mydlow P, Bartlett JA. Pharmacokinetics of lamivudine in human immunodeficiency virus-infected patients with renal dysfunction. Antimicrob. Agents Chemother. 40(6), 1514-1519 (1996).
88. de Souza J, Benet LZ, Huang Y, Storpirtis S. Comparison of bidirectional lamivudine and zidovudine transport using MDCK, MDCK-MDR1, and Caco-2 cell monolayers. J. Pharm. Sci. 98(11), 4413-4419 (2009).
89. Storch CH, Theile D, Lindenmaier H, Haefeli WE, Weiss J. Comparison of the inhibitory activity of anti-HIV drugs on P-glycoprotein. Biochem. Pharmacol. 73(10), 1573-1581 (2007).
90. Murphy RL, Sommadossi JP, Lamson M, Hall DB, Myers M, Dusek A. Antiviral effect and pharmacokinetic interaction between nevirapine and indinavir in persons infected with human immunodeficiency virus type 1. J. Infect. Dis. 179(5), 1116-1123 (1999).
91. Lamson M, Macgregor T, Riska P et al. Nevirapine induces both CYP3A4 and CYP2B6 metabolic pathways. Clin. Pharmacol. Therapeut. 65, 137 (1999).
92. Erickson DA, Mather G, Trager WF, Levy RH, Keirns JJ. Characterization of the in vitro biotransformation of the HIV-1 reverse transcriptase inhibitor nevirapine by human hepatic cytochromes P-450. Drug Metab. Dispos. 27(12), 1488-1495 (1999).
93. Penzak SR, Kabuye G, Mugyenyi P et al. Cytochrome P450 2B6 (CYP2B6) G516T influences nevirapine plasma concentrations in HIV-infected patients in Uganda. HIV Med. 8(2), 86-91 (2007).
94. Mouly S, Lown KS, Kornhauser D et al. Hepatic but not intestinal CYP3A4 displays dose-dependent induction by efavirenz in humans. Clin. Pharmacol. Ther. 72(1), 1-9 (2002).
95. Robertson SM, Maldarelli F, Natarajan V, Formentini E, Alfaro RM, Penzak SR. Efavirenz induces CYP2B6-mediated hydroxylation of bupropion in healthy subjects. J. Acquir. Immune Defic. Syndr. 49(5), 513-519 (2008).
96. Ward BA, Gorski JC, Jones DR, Hall SD, Flockhart DA, Desta Z. The cytochrome P450 2B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: implication for HIV/AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activity. J. Pharmacol. Exp. Ther. 306(1), 287-300 (2003).
97. Hansten PD. Drug Interactions. Applied Therapeutics, Inc., Vancouver, WA, USA (1995).
98. von Moltke LL, Greenblatt DJ, Granda BW et al. Inhibition of human cytochrome P450 isoforms by nonnucleoside reverse transcriptase inhibitors. J. Clin. Pharmacol. 41(1), 85-91 (2001).
99. Zhou S, Yung Chan S, Cher Goh B et al. Mechanism-based inhibition of cytochrome P450 3A4 by therapeutic drugs. Clin. Pharmacokinet. 44(3), 279-304 (2005).
100. Schiller DS, Youssef-Bessler M. Etravirine: a second-generation nonnucleoside reverse transcriptase inhibitor (NNRTI) active against NNRTI-resistant strains of HIV. Clin. Ther. 31(4), 692-704 (2009).
101. Scholler-Gyure, Kakuda TN, Sekar V et al. Pharmacokinetics of darunavir/ritonavir and TMC125 alone and coadministered in HIV-negative volunteers. Antivir. Ther. 12(5), 789-796 (2007).
102. Brown KC, Paul S, Kashuba AD. Drug interactions with new and investigational antiretrovirals. Clin. Pharmacokinet. 48(4), 211-241 (2009).
103. Crauwels HM, Kakuda TN. Drug interactions with new and investigational antiretrovirals. Clin. Pharmacokinet. 49(1), 67-68; author reply 68 (2010).
104. Vourvahis M, Gleave M, Nedderman AN et al. Excretion and metabolism of lersivirine (5-{[3,5-diethyl-1-(2-hydroxyethyl) (3,5-14C2)-1H-pyrazol-4-yl]oxy} benzene-1,3-dic arbonitrile), a next-generation non-nucleoside reverse transcriptase inhibitor, after administration of [14C] lersivirine to healthy volunteers. Drug Metab. Dispos. 38(5), 789-800 (2010).
105. Langdon G, Davis J, Layton G et al. Pharmacokinetic interactions of the next-generation NNRTI UK-453,061 with other antiretrovirals and assessment of safety and tolerability in healthy male subjects. Poster 763. Presented at: 15th Conference on Retroviruses and Opportunistic Infections. Boston, MA, USA, 3-6 February 2008.
106. Clarke SM, Mulcahy FM, Tjia J et al. The pharmacokinetics of methadone in HIV-positive patients receiving the non-nucleoside reverse transcriptase inhibitor efavirenz. Br. J. Clin. Pharmacol. 51(3), 213-217 (2001).
107. Clarke SM, Mulcahy FM, Tjia J et al. Pharmacokinetic interactions of nevirapine and methadone and guidelines for use of nevirapine to treat injection drug users. Clin. Infect. Dis. 33(9), 1595-1597 (2001).
108. McCance-Katz EF, Moody DE, Morse GD et al. Interactions between buprenorphine and antiretrovirals. I. The nonnucleoside reverse-transcriptase inhibitors efavirenz and delavirdine. Clin. Infect. Dis. 43(Suppl. 4), S224-S234 (2006).
109. McCance-Katz EF, Moody DE, Morse GD, Ma Q, Rainey PM. Lack of clinically significant drug interactions between nevirapine and buprenorphine. Am. J. Addict. 19(1), 30-37 (2010).
110. Kappelhoff BS, Crommentuyn KM, de Maat MM, Mulder JW, Huitema AD, Beijnen JH. Practical guidelines to interpret plasma concentrations of antiretroviral drugs. Clin. Pharmacokinet. 43(13), 845-853 (2004).
111. Flexner C. HIV-protease inhibitors. N. Engl. J. Med. 338(18), 1281-1292 (1998).
112. Decker CJ, Laitinen LM, Bridson GW, Raybuck SA, Tung RD, Chaturvedi PR. Metabolism of amprenavir in liver microsomes: role of CYP3A4 inhibition for drug interactions. J. Pharm. Sci. 87(7), 803-807 (1998).
113. Rittweger M, Arastéh K. Clinical pharmacokinetics of darunavir. Clin. Pharmacokinet. 46(9), 739-756 (2007).
114. Yeni P. Tipranavir: a protease inhibitor from a new class with distinct antiviral activity. J. Acquir. Immune Defic. Syndr. 34(Suppl. 1), S91-S94 (2003).
115. Faragon JJ, Piliero PJ. Drug interactions associated with HAART: focus on treatments for addiction and recreational drugs. AIDS Read. 13(9), 433-434, 437-441, 446-450 (2003).
116. Bierman WF, Scheffer GL, Schoonderwoerd A et al. Protease inhibitors atazanavir, lopinavir and ritonavir are potent blockers, but poor substrates, of ABC transporters in a broad panel of ABC transporter-overexpressing cell lines. J. Antimicrob. Chemother. 65(8), 1672-1680 (2010).
117. König SK, Herzog M, Theile D, Zembruski N, Haefeli WE, Weiss J. Impact of drug transporters on cellular resistance towards saquinavir and darunavir. J. Antimicrob. Chemother. 65(11), 2319-2328 (2010).
118. Kassahun K, McIntosh I, Cui D et al. Metabolism and disposition in humans of raltegravir (MK-0518), an anti-AIDS drug targeting the human immunodeficiency virus 1 integrase enzyme. Drug Metab. Dispos. 35(9), 1657-1663 (2007).
119. Iwamoto M, Wenning LA, Mistry GC et al. Atazanavir modestly increases plasma levels of raltegravir in healthy subjects. Clin. Infect. Dis. 47(1), 137-140 (2008).
120. Klibanov OM. Elvitegravir, an oral HIV integrase inhibitor, for the potential treatment of HIV infection. Curr. Opin. Investig. Drugs 10(2), 190-200 (2009).
121. Reese MJ, Savina PM, Generaux GT et al. In vitro investigations into the roles of drug transporters and metabolizing enzymes in the disposition and drug interactions of dolutegravir, a HIV integrase inhibitor. Drug Metab. Dispos. 41(2), 353-361 (2013).
122. Walker DK, Abel S, Comby P, Muirhead GJ, Nedderman AN, Smith DA. Species differences in the disposition of the CCR5 antagonist, UK-427,857, a new potential treatment for HIV. Drug Metab. Dispos. 33(4), 587-595 (2005).
123. Abel S, Russell D, Whitlock LA, Ridgway CE, Muirhead GJ. Effect of maraviroc on the pharmacokinetics of midazolam, lamivudine/zidovudine, and ethinyloestradiol/levonorgestrel in healthy volunteers. Br. J. Clin. Pharmacol. 65(Suppl. 1), 19-26 (2008).
124. Abel S, Jenkins TM, Whitlock LA, Ridgway CE, Muirhead GJ. Effects of CYP3A4 inducers with and without CYP3A4 inhibitors on the pharmacokinetics of maraviroc in healthy volunteers. Br. J. Clin. Pharmacol. 65(Suppl. 1), 38-46 (2008).
125. Abel S, Russell D, Taylor-Worth RJ, Ridgway CE, Muirhead GJ. Effects of CYP3A4 inhibitors on the pharmacokinetics of maraviroc in healthy volunteers. Br. J. Clin. Pharmacol. 65(Suppl. 1), 27-37 (2008).
126. Kumar GN, Dykstra J, Roberts EM et al. Potent inhibition of the cytochrome P-450 3A-mediated human liver microsomal metabolism of a novel HIV protease inhibitor by ritonavir: a positive drug-drug interaction. Drug Metab. Dispos. 27(8), 902-908 (1999).
127. Mathias AA, German P, Murray BP et al. Pharmacokinetics and pharmacodynamics of GS-9350: a novel pharmacokinetic enhancer without anti-HIV activity. Clin. Pharmacol. Ther. 87(3), 322-329 (2010).
128. Bruce R, Winkle R, Custodio J et al. Pharmacotherapies of cobicistat-boosted elvitegravir administered in combination with methadone and buprenorphine/naloxone. Abstract A-1250. Presented at: Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, CA, USA, 9-12 September 2012.
129. Schwartz EL, Brechbühl AB, Kahl P, Miller MA, Selwyn PA, Friedland GH. Pharmacokinetic interactions of zidovudine and methadone in intravenous drug-using patients with HIV infection. J. Acquir. Immune Defic. Syndr. 5(6), 619-626 (1992).
130. McCance-Katz EF, Rainey PM, Jatlow P, Friedland G. Methadone effects on zidovudine disposition (AIDS Clinical Trials Group 262). J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 18(5), 435-443 (1998).
131. McCance-Katz EF, Rainey PM, Friedland G, Kosten TR, Jatlow P. Effect of opioid dependence pharmacotherapies on zidovudine disposition. Am. J. Addict. 10(4), 296-307 (2001).
132. Rainey PM, Friedland GH, Snidow JW et al. The pharmacokinetics of methadone following co-administration with a lamivudine/zidovudine combination tablet in opiate-dependent subjects. Am. J. Addict. 11(1), 66-74 (2002).
133. Rainey PM, Friedland G, McCance-Katz EF et al. Interaction of methadone with didanosine and stavudine. J. Acquir. Immune Defic. Syndr. 24(3), 241-248 (2000).
134. Friedland G, Rainey P, Jatlow P, Andrews L, Damle B, McCance-Katz EF. Pharmacokinetics (PK) of didanosine (ddI) from encapsulated enteric coated bead formulation (EC) vs chewable tablet formulation in patients (pts) on chronic methadone therapy. Presented at: 14th International AIDS Conference. Barcelona, Spain, 7-12 July 2002.
135. McDowell JA, Chittick GE, Ravitch JR, Polk RE, Kerkering TM, Stein DS. Pharmacokinetics of [(14)C]abacavir, a human immunodeficiency virus type 1 (HIV-1) reverse transcriptase inhibitor, administered in a single oral dose to HIV-1-infected adults: a mass balance study. Antimicrob. Agents Chemother. 43(12), 2855-2861 (1999).
136. Yuen GJ, Weller S, Pakes GE. A review of the pharmacokinetics of abacavir. Clin. Pharmacokinet. 47(6), 351-371 (2008).
137. Sellers E, Lam R, Mcdowell J. The pharmacokinetics (PK) of abacavir (ABC) and methadone (M) following co-administration: CNAA 1012. Abstract 305. Presented at:39th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, CA, USA, 26-29 September 1999.
138. Smith PF, Kearney BP, Liaw S et al. Effect of tenofovir disoproxil fumarate on the pharmacokinetics and pharmacodynamics of total, R-, and S-methadone. Pharmacotherapy 24(8), 970-977 (2004).
139. Fung HB, Stone EA, Piacenti FJ. Tenofovir disoproxil fumarate: a nucleotide reverse transcriptase inhibitor for the treatment of HIV infection. Clin. Ther. 24(10), 1515-1548 (2002).
140. Altice FL, Friedland GH, Cooney EL. Nevirapine induced opiate withdrawal among injection drug users with HIV infection receiving methadone. AIDS 13(8), 957-962 (1999).
141. Otero MJ, Fuertes A, Sánchez R, Luna G. Nevirapine-induced withdrawal symptoms in HIV patients on methadone maintenance programme: an alert. AIDS 13(8), 1004-1005 (1999).
142. Heelon MW, Meade LB. Methadone withdrawal when starting an antiretroviral regimen including nevirapine. Pharmacotherapy 19(4), 471-472 (1999).
143. Pinzani V, Faucherre V, Peyriere H, Blayac JP. Methadone withdrawal symptoms with nevirapine and efavirenz. Ann. Pharmacother. 34(3), 405-407 (2000).
144. Staszewski S, Haberl A, Gute P, Nisius G, Miller V, Carlebach A. Nevirapine/didanosine/lamivudine once daily in HIV-1-infected intravenous drug users. Antivir. Ther. (Lond.) 3(Suppl. 4), 55-56 (1998).
145. Stocker H, Kruse G, Kreckel P et al. Nevirapine significantly reduces the levels of racemic methadone and (R)-methadone in human immunodeficiency virus-infected patients. Antimicrob. Agents Chemother. 48(11), 4148-4153 (2004).
146. Clarke SM, Mulcahy FM. Efavirenz therapy in drug users. HIV Med. 1(Suppl 1), 15-17 (2000).
147. Marzolini C, Troillet N, Telenti A, Baumann P, Decosterd LA, Eap CB. Efavirenz decreases methadone blood concentrations. AIDS 14(9), 1291-1292 (2000).
148. Tashima K, Bose T, Gormley J. The potential impact of efavirenz on methadone maintenance. Abstract P0552. Presented at: 9th European Congress of Clinical Microbiology and Infectious Diseases. Berlin, Germany, 21-24 March 1999.
149. McCance-Katz EF, Rainey PM, Smith P et al. Drug interactions between opioids and antiretroviral medications: interaction between methadone, LAAM, and delavirdine. Am. J. Addict. 15(1), 23-34 (2006).
150. Booker B, Smith P, Forrest A et al. Lack of effect on methadone (MET) on the pharmacokinetics (PK) of delavirdine (DLV) & N-delavirdine. Abstract A490. Presented at: 41st Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL, USA, 16-19 December 2001.
151. Schöller-Gyüre M, van den Brink W, Kakuda TN et al. Pharmacokinetic and pharmacodynamic study of the concomitant administration of methadone and TMC125 in HIV-negative volunteers. J. Clin. Pharmacol. 48(3), 322-329 (2008).
152. Crauwels H, Van Heeswijk RPG, Vandevoorde A et al. Pharmacokinetic interaction study between TMC278, a next-generation NNRTI, and methadone. Abstract WEPE0089. Presented at: XVIIIth International AIDS Conference. Vienna, Austria, 18-23 July 2010.
153. Vourvahis M, Wang R, Gruener DM, Bruce RD, Haider S, Tawadrous M. Effect of lersivirine co-administration on pharmacokinetics of methadone in healthy volunteers. Drug Alcohol Depend. 126(1-2), 183-188 (2012).
154. McCance-Katz EF, Rainey PM, Friedland G, Jatlow P. The protease inhibitor lopinavir-ritonavir may produce opiate withdrawal in methadone-maintained patients. Clin. Infect. Dis. 37(4), 476-482 (2003).
155. Cantilena L, Mccrea J, Blazes, D et al. Lack of pharmacokinetic interaction between indinavir and methadone. Clin. Pharmacol. Therapeut. 65(2), 135 (1999).
156. McCance-Katz EF, Rainey PM, Smith P et al. Drug interactions between opioids and antiretroviral medications: interaction between methadone, LAAM, and nelfinavir. Am. J. Addict. 13(2), 163-180 (2004).
157. Hendrix CW, Wakeford J, Wire MB et al. Pharmacokinetics and pharmacodynamics of methadone enantiomers after coadministration with amprenavir in opioid-dependent subjects. Pharmacotherapy 24(9), 1110-1121 (2004).
158. Friedland G, Andrews L, Schreibman T et al. Lack of an effect of atazanavir on steady-state pharmacokinetics of methadone in patients chronically treated for opiate addiction. AIDS 19(15), 1635-1641 (2005).
159. Cao YJ, Smith PF, Wire MB et al. Pharmacokinetics and pharmacodynamics of methadone enantiomers after coadministration with fosamprenavir-ritonavir in opioid-dependent subjects. Pharmacotherapy 28(7), 863-874 (2008).
160. Gerber JG, Rosenkranz S, Segal Y et al.; ACTG 401 Study Team. Effect of ritonavir/saquinavir on stereoselective pharmacokinetics of methadone: results of AIDS Clinical Trials Group (ACTG) 401. J. Acquir. Immune Defic. Syndr. 27(2), 153-160 (2001).
161. Shelton MJ, Cloen D, DiFrancesco R et al. The effects of once-daily saquinavir/minidose ritonavir on the pharmacokinetics of methadone. J. Clin. Pharmacol. 44(3), 293-304 (2004).
162. McCance-Katz EF, Farber S, Selwyn PA, O'Connor A. Decrease in methodone levels with nelfinavir mesylate. Am. J. Psychiatry 157(3), 481 (2000).
163. Clarke S, Mulcahy F, Bergin C et al. Absence of opioid withdrawal symptoms in patients receiving methadone and the protease inhibitor lopinavir-ritonavir. Clin. Infect. Dis. 34(8), 1143-1145 (2002).
164. Stevens RC, Rapaport S, Maroldo-Connelly L, Patterson JB, Bertz R. Lack of methadone dose alterations or withdrawal symptoms during therapy with lopinavir/ritonavir. J. Acquir. Immune Defic. Syndr. 33(5), 650-651 (2003).
165. McCance-Katz EF, Moody DE, Smith PF et al. Interactions between buprenorphine and antiretrovirals. II. The protease inhibitors nelfinavir, lopinavir/ritonavir, and ritonavir. Clin. Infect. Dis. 43 (Suppl. 4), S235-S246 (2006).
166. Kaletra® (lopinavir/ritonavir), product information. Abbott Laboratories, IL, USA (2009).
167. Tossonian HK, Raffa JD, Grebely J et al. Methadone dosing strategies in HIV-infected injection drug users enrolled in a directly observed therapy program. J. Acquir. Immune Defic. Syndr. 45(3), 324-327 (2007).
168. Aptivus® (tipranavir), product information. Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, USA (2005).
169. Sekar V, Tomaka F, Lefebvre E et al. Pharmacokinetic interactions between darunavir/ritonavir and opioid maintenance therapy using methadone or buprenorphine/naloxone. J. Clin. Pharmacol. 51(2), 271-278 (2011).
170. Anderson MS, Mabalot Luk JA, Hanley WD et al. Effect of raltegravir on the pharmacokinetics of methadone. J. Clin. Pharmacol. 50(12), 1461-1466 (2010).
171. Iwamoto M, Wenning LA, Nguyen BY et al. Effects of omeprazole on plasma levels of raltegravir. Clin. Infect. Dis. 48(4), 489-492 (2009).
172. Song I, Mark S, Borland J et al. Dolutegravir has no effect on pharmacokinetics of methadone or oral contraceptives with norgestimate and ethinyl estradiol. Abstract 535. Presented at: 20th Conference on Retroviruses and Opportunistic Infections. Atlanta, GA, USA, 3-6 March 2013.
173. CSAT. Clinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction. Department of Health and Human Services, Rockville, MD, USA (2004).
174. Altice FL, Bruce RD, Lucas GM et al.; BHIVES Collaborative. HIV treatment outcomes among HIV-infected, opioid-dependent patients receiving buprenorphine/naloxone treatment within HIV clinical care settings: results from a multisite study. J. Acquir. Immune Defic. Syndr. 56(Suppl. 1), S22-S32 (2011).
175. Baker J, Rainey PM, Moody DE, Morse GD, Ma Q, McCance-Katz EF. Interactions between buprenorphine and antiretrovirals: nucleos(t)ide reverse transcriptase inhibitors (NRTI) didanosine, lamivudine, and tenofovir. Am. J. Addict. 19(1), 17-29 (2010).
176. Boas RA, Villiger JW. Clinical actions of fentanyl and buprenorphine. The significance of receptor binding. Br. J. Anaesth. 57(2), 192-196 (1985).
177. Bruce RD, Altice FL. Three case reports of a clinical pharmacokinetic interaction with buprenorphine and atazanavir plus ritonavir. AIDS 20(5), 783-784 (2006).
178. McCance-Katz EF, Moody DE, Morse GD et al. Interaction between buprenorphine and atazanavir or atazanavir/ritonavir. Drug Alcohol Depend. 91(2-3), 269-278 (2007).
179. Vergara-Rodriguez P, Tozzi MJ, Botsko M et al.; BHIVES Collaborative. Hepatic safety and lack of antiretroviral interactions with buprenorphine/ naloxone in HIVinfected opioid-dependent patients. J. Acquir. Immune Defic. Syndr. 56(Suppl. 1), S62-S67 (2011).
180. Bruce RD. Additional explanation for lack of pharmacodynamic interaction between atazanavir and buprenorphine reported by Vergara-Rodriquez et al. J. Acquir. Immune Defic. Syndr. 58(4), e112; author reply e112-e113 (2011).
181. Reyataz®, product information. Bristol-Myers Sqibb, NY, USA (2011).
182. Bruce RD, Altice FL, Moody DE et al. Pharmacokinetic interactions between buprenorphine/naloxone and once-daily lopinavir/ritonavir. J. Acquir. Immune Defic. Syndr. 54(5), 511-514 (2010).
183. Gruber VA, Rainey PM, Moody DE et al. Interactions between buprenorphine and the protease inhibitors darunavir-ritonavir and fosamprenavir-ritonavir. Clin. Infect. Dis. 54(3), 414-423 (2012).
184. Bruce RD, Altice FL, Moody DE et al. Pharmacokinetic interactions between buprenorphine/naloxone and tipranavir/ritonavir in HIV-negative subjects chronically receiving buprenorphine/naloxone. Drug Alcohol Depend. 105(3), 234-239 (2009).
185. Bruce RD, Moody DE, Fang WB, Chodkowski D, Andrews L, Friedland GH. Tipranavir/ritonavir induction of buprenorphine glucuronide metabolism in HIV-negative subjects chronically receiving buprenorphine/naloxone. Am. J. Drug Alcohol Abuse 37(4), 224-228 (2011).
186. Bruce R, Moody D, Chodkowski D et al. Pharmacokinetic interactions between buprenorphine/naloxone and raltegravir. Abstract MOPE176. Presented at: 6th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention. Rome, Italy, 17-20 July 2011.
187. Berk SI, Litwin AH, Arnsten JH, Du E, Soloway I, Gourevitch MN. Effects of pegylated interferon β-2b on the pharmacokinetic and pharmacodynamic properties of methadone: a prospective, nonrandomized, crossover study in patients coinfected with hepatitis C and HIV receiving methadone maintenance treatment. Clin. Ther. 29(1), 131-138 (2007).
188. Gupta SK, Sellers E, Somoza E, Angles L, Kolz K, Cutler DL. The effect of multiple doses of peginterferon β-2b on the steady-state pharmacokinetics of methadone in patients with chronic hepatitis C undergoing methadone maintenance therapy. J. Clin. Pharmacol. 47(5), 604-612 (2007).
189. Sulkowski M, Wright T, Rossi S et al. Peginterferon β-2a does not alter the pharmacokinetics of methadone in patients with chronic hepatitis C undergoing methadone maintenance therapy. Clin. Pharmacol. Ther. 77(3), 214-224 (2005).
190. Kempf DJ, Klein C, Chen HJ et al. Pharmacokinetic enhancement of the hepatitis C virus protease inhibitors VX-950 and SCH 503034 by co-dosing with ritonavir. Antivir. Chem. Chemother. 18(3), 163-167 (2007).
191. Ghosal A, Yuan Y, Tong W et al. Characterization of human liver enzymes involved in the biotransformation of boceprevir, a hepatitis C virus protease inhibitor. Drug Metab. Dispos. 39(3), 510-521 (2011).
192. Van Heeskwijk R, Vandevoorde A, Verboven P et al. The pharmacokinetic interaction between methadone and the investigational HCV protease inhibitor telaprevir. Abstract 654. Presented at: 46th Annual Meeting of the European Association for the Study of the Liver. Berlin, Germany, 30 March -3 April 2011.
193. Luo X, Trevejo J, van Heeswijk RP, Smith F, Garg V. Effect of telaprevir on the pharmacokinetics of buprenorphine in volunteers on stable buprenorphine/naloxone maintenance therapy. Antimicrob. Agents Chemother. 56(7), 3641-3647 (2012).
194. Hulskotte E, Feng HP, Bruce RD et al. Pharmacokinetic interactions between HCV protease inhibitor boceprevir and methadone or buprenorphine in subjects on stable maintenance therapy. Presented at: 7th International Workshop on Clinical Pharmacology of Hepatitis Therapy. Cambridge, MA, USA, 27-28 June 2012.
195. Denning J, Cornpropst MT, Clemons D et al. Lack of effect of the nucleotide analog polymerase inhibitor PSI-7977 on methadone PK and PD. Presented at: American Association for the Study of Liver Diseases Annual Meeting. San Francisco, CA, USA, 6-9 November 2011.
196. Ouwerkerk-Mahadevan O, Beaumont-Mauviel M, Peeters M, Akuma SH, Sekar V. The pharmacokinetic interaction between the investigational NS3/4A HCV protease inhibitor TMC435 and methadone. Presented at: American Association for the Study of Liver Diseases Annual Meeting. Boston, MA, USA, 9-13 November 2012.
197. Handelsman L, Cochrane KJ, Aronson MJ, Ness R, Rubinstein KJ, Kanof PD. Two new rating scales for opiate withdrawal. Am. J. Drug Alcohol Abuse 13(3), 293-308 (1987).
198. Saber-Tehrani AS, Bruce RD, Altice FL. Pharmacokinetic drug interactions and adverse consequences between psychotropic medications and pharmacotherapy for the treatment of opioid dependence. Am. J. Drug Alcohol Abuse 37(1), 1-11 (2011).
199. Cobb MN, Desai J, Brown LS Jr, Zannikos PN, Rainey PM. The effect of fluconazole on the clinical pharmacokinetics of methadone. Clin. Pharmacol. Ther. 63(6), 655-662 (1998).
200. Ehret GB, Voide C, Gex-Fabry M et al. Drug-induced long QT syndrome in injection drug users receiving methadone: high frequency in hospitalized patients and risk factors. Arch. Intern. Med. 166(12), 1280-1287 (2006).